KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Other Non-Current Liabilities (2017 - 2025)

Historic Other Non-Current Liabilities for Moderna (MRNA) over the last 9 years, with Q3 2025 value amounting to $281.0 million.

  • Moderna's Other Non-Current Liabilities rose 181.16% to $281.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $281.0 million, marking a year-over-year increase of 181.16%. This contributed to the annual value of $267.0 million for FY2024, which is 429.69% up from last year.
  • Moderna's Other Non-Current Liabilities amounted to $281.0 million in Q3 2025, which was up 181.16% from $276.0 million recorded in Q2 2025.
  • In the past 5 years, Moderna's Other Non-Current Liabilities registered a high of $281.0 million during Q3 2025, and its lowest value of $1.0 million during Q2 2021.
  • Over the past 5 years, Moderna's median Other Non-Current Liabilities value was $172.0 million (recorded in 2023), while the average stood at $166.6 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first tumbled by 5419.15% in 2021, then soared by 1120000.0% in 2022.
  • Over the past 5 years, Moderna's Other Non-Current Liabilities (Quarter) stood at $76.0 million in 2021, then surged by 77.63% to $135.0 million in 2022, then soared by 89.63% to $256.0 million in 2023, then rose by 4.3% to $267.0 million in 2024, then rose by 5.24% to $281.0 million in 2025.
  • Its last three reported values are $281.0 million in Q3 2025, $276.0 million for Q2 2025, and $274.0 million during Q1 2025.